Latest News and Events
Filter by
Selections
September 11, 2025
Arrowhead Pharmaceuticals Files Complaint for Declaratory Judgment Against Ionis Pharmaceuticals
Read MoreSeptember 10, 2025
Arrowhead Pharmaceuticals Requests Regulatory Clearance to Initiate Phase 1/2a Study of ARO-MAPT for the Treatment of Alzheimer’s Disease and Other Tauopathies
Read MoreSeptember 2, 2025
Arrowhead Pharmaceuticals and Novartis Enter into a Global License and Collaboration Agreement
Read MoreAugust 27, 2025
Arrowhead Pharmaceuticals to Participate in Upcoming September 2025 Conferences
Read MoreAugust 13, 2025
Arrowhead Pharmaceuticals Redeems Approximately $50 Million of Arrowhead Stock and Will Receive Approximately $50 Million in Cash in Satisfaction of Milestone from Sarepta Therapeutics
Read MoreAugust 1, 2025
Arrowhead Subsidiary Visirna Sells Rights to Hypertriglyceridemia Candidate Plozasiran in Greater China to Sanofi
Read MoreJuly 28, 2025
Arrowhead Pharmaceuticals Earns $100 Million Milestone from Sarepta Therapeutics
Read MoreJuly 24, 2025